We narrowed to 52 results for: venus

...al. (2006) Cerulean, Venus, and VenusY67C FRET reference standards mCerulean-mVenus FRET efficiency standards...mCerulean mVenus 433 0.49 527 104,000 0.64 5.3 2.3 mCerulean N1 , mVenus N1 mTurquoise2 mVenus 434 0.93...527 104,000 0.64 5.9 2.3 pmTurquoise2-N1 , mVenus N1 , pmVenus(L68V)-mTurquoise2 mTurquoise2 mNeonGreen ...CYPet-N1 , YPet-N1 mTFP1 mVenus 462 0.85 527 104,000 0.64 6.0 2.9 mTFP1-N1 , mVenus N1 mTFP1 mCitrine 462...C1 , pDx_mScarlet3-SYFP2 mVenus mKO2 515 0.64 565 63,800 0.62 5.7 2.9 mVenus N1 , mKO2-N1 mOrange2 mCherry...via flexible peptide linkers mCerulean, mVenus, and Amber (mVenus Y67C) FRET standards and cloning backbones... resonance energy transfer mCerulean, mVenus, and Amber (mVenus Y67C) constructs for measuring energy ...

...activation Slaviero et al., 2024 iLMO: RLuc-NpHR Venus-Rluc8 NpHR hCTZ Cl - influx Neuronal inhibition ...

...the acceptor fluorophore, a circularly permuted Venus. In the case of pHlash, the signal from the fluorophore...host-tropism. These tools open up many powerful avenues through which one can examine molecular events ...

...as a nonprofit under the United States Internal Revenue Code 501(c)(3). That means we were formed to benefit... are able to fulfill our mission by generating revenue through distribution of research materials. Our..." is a bit misleading. Nonprofits can generate revenue (as Addgene does through materials distribution... nonprofits should have some level of positive revenue to build reserves so the company is sustainable...The difference is what nonprofits do with their revenue. A nonprofit organization cannot distribute profits...

... For example, the APT1-mVenus fusion localizes at the Golgi, whereas the mVenus-APT1 fusion does not (... (figure 2). In the mVenus-APT1, a lipidation motif, which is needed for Golgi localization, is occluded...therefore this protein is mislocalized. The APT1-mVenus fusion is clearly a better choice to work with....

...significantly enhanced photostability — 25-fold over mVenus and 4-fold over the previous best performer mGold...imaging of COS-7 cells expressing LifeAct fused to mVenus, mGold2s, or mGold2t. Bottom: Quantification of...BY-NC-ND license. If you’re currently using mVenus or mCitrine, or if existing yellow fluorescent ...

... fused to mVenus linked to a mitochondrial localization sequence TOM20 (pTriEX Tom20 mVenus BoPD). In ...

...expressed a fusion of keratin with mGold (top) and mVenus (bottom). Cells were imaged every 30 seconds for... up to 5-fold more photostable and as bright to mVenus, the parent YFP, and is the most photostable YFP...

...Bacterial Expression moxVenus 514 526 44 Monomer (A206K) moxVenus - Mammalian Expression mVenus 515 528 53 6 ...6 Monomer (A206K) mVenus N1 - Mammalian Expression mVenus C1 - Mammalian Expression pKT0090 - Yeast Expression...Expression mVenus-pBAD - Bacterial Expression SYFP2 515 527 69 6 Monomer (A206K) pSYFP2-C1 - Mammalian...

...RNA without tagging,” she said. “It opens a new avenue of modifying and manipulating endogenous eukaryotic...

...silencer. The current work also proposes promising avenues for future engineering to shift the spectra and...

...not make changes to the genome, thus providing an avenue for temporary/reversible CRISPR modification. In...

...adult. My initial research directions followed that avenue with projects studying developmentally programmed...

... Abitua and the other organizers found several avenues to keep the audience engaged. They first sent a...

...enabled scientists to pursue creative research avenues previously unavailable to them. With these fantastic...

... The plasmid for co-expressing mTurquoise2 with mVenus as a reference protein is available from Addgene...

...will improve the utility of CRISPR/Cas9 in new avenues of research. The use of multiple gRNAs targeting...

...graduate students will pursue this newly available avenue. Interestingly, both of these changes share a common...

...causes of some human conditions, opening up new avenues for therapeutics that treat disease at the molecular...

...Mathis, N., Allam, A., Tálas, A., Kissling, L., Benvenuto, E., Schmidheini, L., Schep, R., Damodharan, T...